Keyphrases
Monoclonal Antibody
100%
Metastatic Colorectal Cancer (mCRC)
100%
Brazil
100%
Budget Impact
100%
Minas Gerais
100%
Cetuximab
83%
Bevacizumab
83%
Panitumumab
83%
Lawsuit
33%
Cancer Treatment
16%
National Database
16%
Biological Medicines
16%
Litigation
16%
Cost Increase
16%
KRAS mutation
16%
Unified Health System
16%
Conventional Chemotherapy
16%
Cost of Goods
16%
Budget Impact Analysis
16%
Cancer Costs
16%
Anti-epidermal Growth Factor Receptor Monoclonal Antibodies
16%
Medicine and Dentistry
Monoclonal Antibody
100%
Metastatic Colorectal Cancer
100%
Health Care Cost
85%
Cetuximab
71%
Bevacizumab
71%
Panitumumab
71%
Medicine
14%
Health System
14%
Anti-Epidermal Growth Factor Receptor
14%
Cancer Treatment
14%
Chemotherapy
14%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Colorectal Cancer
100%
Monoclonal Antibody
100%
Cetuximab
71%
Panitumumab
71%
Bevacizumab
71%
Epidermal Growth Factor Receptor
14%
Malignant Neoplasm
14%
Chemotherapy
14%
Agricultural and Biological Sciences
Monoclonal Antibody
100%
Panitumumab
71%
Cetuximab
71%
Bevacizumab
71%
KRAS
14%
Epidermal Growth Factor Receptor
14%
Immunology and Microbiology
Monoclonal Antibody
100%
Cetuximab
71%
Bevacizumab
71%
Panitumumab
71%
Epidermal Growth Factor
14%